Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her…

POPULAR TAGS

Celyad cuts deal with Ono Pharmaceutical on immunotherapy treatment

Written by DS on in the category news with the tags , , .


Japan's Ono Pharmaceutical will license a cancer treatment of Celyad. The collaboration is very welcome, as two weeks ago, the Walloon company had to share disappointing results of C-Cure, a stem cell therapy for heart failure. Ono Pharmaceutical already placed Opdivo on the market, a very promising cancer immunotherapy.

Ono Pharmaceutical will license a cancer treatment of Celyad, which also falls in the category of immunotherapy. It concerns NKR-2-T, which Celyad CEO Christian Homsy previously labeled "Swiss Army Knife", as it does not recognize one, but several kinds of tumors. The therapy is sparsely being tested on cancer patients.

It is noteworthy that Ono Pharmaceutical chose the allogeneic form of treatment, in which cells from a donor are used. On the autologous treatment, Ono Pharmaceutical only took an option.

In an inital phase, Ono Pharmaceutical pays 11.25 million euros to Celyad for the license. This can be topped up with milestone payments, depending on the success of the treatment. Celyad might earn up to 282 million euros.

Ono Pharmaceutical only closed a deal for Japan, South Korea and Taiwan. Celyad hopes to come to a similar agreement for other countries. "There is a lot of interest," stated Homsy yesterday, "important results are coming up in the next months."

Celyad made in 2015 a major turnaround by focusing on cancer, where it previously only focused on heart failure. According to Homsy, this is the way to go as he recently wrote in a letter to the stockholders: "Christopher Columbus departed on a journey to find a new route to India, but eventually discovered America."

Read more about: , , .

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio V-Bio Ventures Turnstone Itera Life Science Janssen XpandInnovation KU Leuven Biowin UGent GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.